Wuhan Frasergen Bioinformatics Co., Ltd.
PrivateLast Round
Series C
Feb 2, 2023
Total Funding Raised
$7.54M
Company Overview
Wuhan Frasergen Bioinformatics Co., Ltd. operates in Healthcare & Life Sciences and is based in Wuhan. Its latest recorded funding round was a Series C round in February 2023.
Wuhan Frasergen Bioinformatics Co., Ltd. is a biotechnology company that provides bioinformatics and genomics research services, including sequencing, data analysis, and molecular marker development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Biotech Equipment, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Wuhan Frasergen Bioinformatics Co., Ltd. Comparables
Compare Wuhan Frasergen Bioinformatics Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Guangzhou Genedenovo Biotechnology Co., Ltd. | 87% | |
| Annoroad Gene Technology | 81% | |
| Novogene Co. Ltd. | 79% |
For institutional investors. Book with your work email.
Wuhan Frasergen Bioinformatics Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 2, 2023 | ||||
| Series B Extension | Jan 25, 2018 | ||||
| Series B | Nov 12, 2017 | ||||
| Series A | Jun 1, 2017 |
For institutional investors. Book with your work email.
Wuhan Frasergen Bioinformatics Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Series B |
| 融和资本 | Series A |
| 合源资本管理有限公司 | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 2, 2023
Raised Series C round.
- Jan 25, 2018
Raised Series B Extension round with investment from 合源资本管理有限公司.
For institutional investors. Book with your work email.
Wuhan Frasergen Bioinformatics Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Wuhan Frasergen Bioinformatics Co., Ltd.'s valuation, stock price, and market status.
Is Wuhan Frasergen Bioinformatics Co., Ltd. a public or private company?
Wuhan Frasergen Bioinformatics Co., Ltd. is a private company.
What is the current stock price of Wuhan Frasergen Bioinformatics Co., Ltd.?
Wuhan Frasergen Bioinformatics Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Wuhan Frasergen Bioinformatics Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Wuhan Frasergen Bioinformatics Co., Ltd. worth (valuation)?
Valuation information for Wuhan Frasergen Bioinformatics Co., Ltd. is not publicly available.
Can I buy Wuhan Frasergen Bioinformatics Co., Ltd. stock?
Wuhan Frasergen Bioinformatics Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Wuhan Frasergen Bioinformatics Co., Ltd.'s last funding round?
Wuhan Frasergen Bioinformatics Co., Ltd.'s most recent funding round was Series C on February 2, 2023.
Who are the main investors in Wuhan Frasergen Bioinformatics Co., Ltd.?
Key investors in Wuhan Frasergen Bioinformatics Co., Ltd. include Alwin Capital.
Will Wuhan Frasergen Bioinformatics Co., Ltd. IPO soon?
No public IPO plans have been announced for Wuhan Frasergen Bioinformatics Co., Ltd..
How can I track Wuhan Frasergen Bioinformatics Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Wuhan Frasergen Bioinformatics Co., Ltd.'s shares on secondary markets.